Mark T. Deming, Shareholder, Polsinelli to Speak at TKG’s Event
New York, NY, December 12, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Mark T. Deming, Shareholder, Polsinelli will speak at the Knowledge Group’s webcast entitled: “The Hatch-Waxman Act: Recent Amendments and Developments Live Webcast.” This event is scheduled for December 14, 2017 at 12:00 PM - 1:30 PM ET.
For further details, please visit: https://www.theknowledgegroup.org/webcasts/healthcare/health-law-healthcare/the-hatch-waxman-act
About Mark T. Deming
Mark is shareholder in Polsinelli’s Hatch-Waxman litigation group. Mark’s practice involves the representation of both brand and generic pharmaceutical companies. He is involved in all aspects of case developments, from initial assessment to discovery, motions practice, claim construction, expert witnesses, trial and appeal. Polsinelli’s Hatch-Waxman team represents some of the world’s largest and most influential generic, brand, and specialty pharmaceutical companies. They have litigated a broad variety of drug products, many in first-to-file cases as well as in subsequent-filer cases, and have first-chair experience litigating Hatch-Waxman cases in key venues, including Delaware, New Jersey, and the Eastern District of Texas. Their knowledge of the pharmaceutical sciences includes compositions and APIs, formulations (oral dosage forms, controlled release, ODTs, transdermal, topical, ophthalmic, transmucosal, parenteral, etc.), methods of use, polymorphs, enantiomers, drug delivery devices, and methods of manufacture.
About Polsinelli
Polsinelli is an Am Law 100 firm with more than 800 attorneys in 19 offices, serving corporations, institutions, and entrepreneurs nationally. Ranked in the top five percent of law firms for client service*, the firm has risen more than 100 spots in Am Law's annual firm ranking over the past six years. Polsinelli attorneys provide practical legal counsel infused with business insight, and focus on health care, financial services, real estate, intellectual property, mid-market corporate, and business litigation. Polsinelli attorneys have depth of experience in 100 service areas and 70 industries. The firm can be found online at www.polsinelli.com. Polsinelli PC. In California, Polsinelli LLP.
Event Synopsis:
The Hatch-Waxman Act is one of the most important regulators of competition between brand and generic pharmaceutical companies. Because of its provisions, the pharma industry has continuously achieved balance when it comes to patent protection and entry of a new drug. By requiring the abbreviated new drug application (ANDA) process, Hatch-Waxman regulates the approval of a "bioequivalent" generic drug while protecting the patent rights of an existing brand drug.
Because of its significant impact on both brand and generic drug companies, it is imperative for the pharma industry to keep abreast of the latest developments in Hatch-Waxman Act: amendments, as well as potential changes in the year ahead.
Join a panel of key thought leaders and practitioners assembled by The Knowledge Group as they bring the audience to a road beyond the basics of the Hatch-Waxman Act. Listen as they delve into an in-depth analysis of the latest developments and trends involving FDA applications — approvals and rejections. Speakers will also provide the audience with practical strategies when it comes to ANDA litigation.
This live webcast will discuss the following key topics:
The Hatch-Waxman Act: Overview and Legal Framework
Latest Developments
The Abbreviated New Drug Application (ANDA) Process
Latest Developments in ANDA Litigation
Recent FDA Applications
The Hatch-Waxman Act in 2018 – An Outlook
About The Knowledge Group /The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
For further details, please visit: https://www.theknowledgegroup.org/webcasts/healthcare/health-law-healthcare/the-hatch-waxman-act
About Mark T. Deming
Mark is shareholder in Polsinelli’s Hatch-Waxman litigation group. Mark’s practice involves the representation of both brand and generic pharmaceutical companies. He is involved in all aspects of case developments, from initial assessment to discovery, motions practice, claim construction, expert witnesses, trial and appeal. Polsinelli’s Hatch-Waxman team represents some of the world’s largest and most influential generic, brand, and specialty pharmaceutical companies. They have litigated a broad variety of drug products, many in first-to-file cases as well as in subsequent-filer cases, and have first-chair experience litigating Hatch-Waxman cases in key venues, including Delaware, New Jersey, and the Eastern District of Texas. Their knowledge of the pharmaceutical sciences includes compositions and APIs, formulations (oral dosage forms, controlled release, ODTs, transdermal, topical, ophthalmic, transmucosal, parenteral, etc.), methods of use, polymorphs, enantiomers, drug delivery devices, and methods of manufacture.
About Polsinelli
Polsinelli is an Am Law 100 firm with more than 800 attorneys in 19 offices, serving corporations, institutions, and entrepreneurs nationally. Ranked in the top five percent of law firms for client service*, the firm has risen more than 100 spots in Am Law's annual firm ranking over the past six years. Polsinelli attorneys provide practical legal counsel infused with business insight, and focus on health care, financial services, real estate, intellectual property, mid-market corporate, and business litigation. Polsinelli attorneys have depth of experience in 100 service areas and 70 industries. The firm can be found online at www.polsinelli.com. Polsinelli PC. In California, Polsinelli LLP.
Event Synopsis:
The Hatch-Waxman Act is one of the most important regulators of competition between brand and generic pharmaceutical companies. Because of its provisions, the pharma industry has continuously achieved balance when it comes to patent protection and entry of a new drug. By requiring the abbreviated new drug application (ANDA) process, Hatch-Waxman regulates the approval of a "bioequivalent" generic drug while protecting the patent rights of an existing brand drug.
Because of its significant impact on both brand and generic drug companies, it is imperative for the pharma industry to keep abreast of the latest developments in Hatch-Waxman Act: amendments, as well as potential changes in the year ahead.
Join a panel of key thought leaders and practitioners assembled by The Knowledge Group as they bring the audience to a road beyond the basics of the Hatch-Waxman Act. Listen as they delve into an in-depth analysis of the latest developments and trends involving FDA applications — approvals and rejections. Speakers will also provide the audience with practical strategies when it comes to ANDA litigation.
This live webcast will discuss the following key topics:
The Hatch-Waxman Act: Overview and Legal Framework
Latest Developments
The Abbreviated New Drug Application (ANDA) Process
Latest Developments in ANDA Litigation
Recent FDA Applications
The Hatch-Waxman Act in 2018 – An Outlook
About The Knowledge Group /The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories